Deutsche Bank’s Inhibikase Therapeutics IKT Stock Holding History
Bought
Maintained
Sold
Other funds holding IKT
SL
Deutsche Bank's IKT Position: Q3 2026 in Review
Deutsche Bank reduced its Inhibikase Therapeutics (IKT) stake by 13% in Q3 2026, selling an estimated $36.2K and leaving 110,779 shares worth $228K. The position accounts for ﹤0.01% of the portfolio, ranked #3023.
Deutsche Bank first reported a position in IKT in Q3 2025 and has held it in 5 quarters since. The position peaked at $257K in Q2 2026. 110 funds tracked by Wall St. Rank hold IKT as of Q3 2026.
- Deutsche Bank held 110,779 shares of Inhibikase Therapeutics worth $228K as of Q3 2026.
- Deutsche Bank sold 15,898 Inhibikase Therapeutics shares in Q3 2026, an estimated $36.2K.
- Inhibikase Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q3 2026, its #3023 holding.
- Deutsche Bank first reported a position in Inhibikase Therapeutics in Q3 2025 and has held it in 5 quarters since.
- Deutsche Bank's Inhibikase Therapeutics position peaked at $257K in Q2 2026.
- 110 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q3 2026.
Based on Deutsche Bank's 13F filing for Q3 2026, filed 6 Nov 2026.